⌘K

Home/Filings/4/0001209191-24-001074

4//SEC Filing

Kanesa-thasan Niranjan 4

Accession 0001209191-24-001074

CIK 0001786255other

View on SEC.gov Company Profile

Filed

Jan 4, 7:00 PM ET

Accepted

Jan 5, 7:18 PM ET

Size

20.7 KB

Accession

0001209191-24-001074

Insider Transaction Report

Form 4

Period: 2023-01-04

Icosavax, Inc.ICVX

Kanesa-thasan Niranjan

Chief Medical Officer

Transactions

Exercise/Conversion
Common Stock
2023-01-04$0.84/sh+13,806$11,597→ 237,786 total
Sale
Common Stock
2023-01-04$15.70/sh−106,373$1,670,460→ 223,980 total
Exercise/Conversion
Common Stock
2023-01-04$1.04/sh+74,648$77,634→ 312,434 total
Exercise/Conversion
Common Stock
2023-01-04$5.90/sh+11,947$70,487→ 324,381 total
Exercise/Conversion
Common Stock
2023-01-04$15.00/sh+5,972$89,580→ 330,353 total
Exercise/Conversion
Stock Option (Right to Buy)
2023-01-04−13,806→ 2,511 total
Exercise: $0.84Exp: 2030-08-06→ Common Stock (13,806 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2023-01-04−5,972→ 118,528 total
Exercise: $15.00Exp: 2031-07-27→ Common Stock (5,972 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2023-01-04−74,648→ 42,193 total
Exercise: $1.04Exp: 2031-01-28→ Common Stock (74,648 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2023-01-04−11,947→ 108,369 total
Exercise: $5.90Exp: 2031-04-11→ Common Stock (11,947 underlying)

Footnotes (5)

[F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.70 to $15.78. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F2]25% of the shares subject to the option vested on April 1, 2021, and 1/48th of the shares subject to the option vest monthly thereafter.
[F3]25% of the shares subject to the option vested on January 14, 2022, and 1/48th of the shares subject to the option vest monthly thereafter.
[F4]25% of the shares subject to the option vested on March 19, 2022, and 1/48th of the shares subject to the option vest monthly thereafter.
[F5]1/48th of the shares subject to the option vest monthly following July 28, 2021, the vesting commencement date.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

Icosavax, Inc.

CIK 0001786255

Entity typeother

Related Parties

1

filerCIK 0001874021

Filing Metadata

Form type: 4
Filed: Jan 4, 7:00 PM ET
Accepted: Jan 5, 7:18 PM ET
Size: 20.7 KB

View on SEC.gov